SK biopharmaceuticals

326030 · KOSPI · Health Care · LARGE CAP

Rights offering (paid-in capital increase) decision (subsidiary)

Capital raise(Rights offering (paid-in capital increase) decision (subsidiary))· FILED 2026-03-09· RCEPT 20260309801187

About this filing

A decision to issue new shares (for cash, or free to existing shareholders), with the number of shares, the method and the use of proceeds.

Why companies file it: Share issues are disclosed because they change the share count.

A full English translation of this filing is not available yet. The original (in Korean) is linked below.

Filed2026-03-09, Rights offering (paid-in capital increase) decision (subsidiary)
SourceDART rcept 20260309801187 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-03-09 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).